Funding cuts by countries that make major contributions to foreign aid may cause surges in global HIV. Funding cuts by five countries that provided over 90% of total international HIV funding as of ...

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province 215000, China ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency virus (HIV), a discovery that brings medical experts one step closer to a cure ...

ViiV Healthcare is looking to investigate twice-yearly dosing of its human immunodeficiency virus (HIV) therapy, which has been able to ... The Phase IIb multi-centre, randomised, open-label study ...

known as acute HIV infection (Stage 1), chronic HIV infection (Stage 2), and AIDS (Stage 3). During primary infection, the symptoms are caused by the virus itself, leading to fever, fatigue, and ...

Human immunodeficiency virus ... of the HIV reservoir cells. The team revealed that they would combine the CRISPR therapeutics and receptor-targeting reagents and move to preclinical models ...

Abstract: The scarcity of labeled data poses a significant challenge for deep learning-based medical image segmentation. To address this, this study introduces the novel Foundation Model-based ...

An effective HIV-1 vaccine must therefore elicit antibodies that can neutralize many variants of the virus. While broadly neutralizing antibodies (bnAbs) have been isolated from HIV-1 infected ...

They're not a cure for HIV. These medicines aim to: Control the growth of the virus Improve how well your immune system works Slow or stop symptoms Prevent transmission of HIV to others By taking ...